http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
전상용 한국법경제학회 2017 법경제학연구 Vol.14 No.3
Contract law has its roots in the binding power of contracts. Without such power, contracting parties do not have incentives to comply with contract. Consequently, transaction costs would surge and social welfare would be reduced. Nonetheless, voting agreements in Korea among shareholders have surprisingly weak binding power. According to a handful number of lower court decisions, specific performance nor injunction for voting agreements are not granted. This means that the non-breaching party would have to wait years until the judgment on specific performance becomes final and conclusive. Taking into account that timing matters critically in contexts where voting agreements are made, this is not different from excluding specific performance and injunction as a remedy for voting agreements. In this paper, the relationship between the binding power of contract and efficiency is introduced in II. Calebresi and Melamed's and Ulen's precedent researches on remedies for entitlements and contracts are reviewed in Ⅲ. In Ⅳ, that binding agreements are made in closed corporations with high volatility of corporation value is noted, and that under such situation, specific performance and injunction are more efficient remedies compared with expectation damages is shown through two approaches: one of transaction cost and the other regarding game-tree-like expression. It is concluded that the binding power of voting agreements in Korea is excessively weak, resulting in great increase of transaction costs. In conclusion, this paper argues that specific performance and injunction should be explicitly allowed as a remedy for voting agreements among shareholders in Korea. Moreover, the essential function of contract law is again reviewed from a law and economics perspective, and a novel research method called "game-tree-like expression" is suggested. 계약법은 계약의 구속력에서 출발한다. 계약에 구속력이 없다면, 계약 당사자들에게는 계약을 준수할 유인이 없어지고, 계약에 따른 급부가 원만하게 실현되리라는 기대가 훼손되어, 거래비용이 크게 증가하고 사회적 후생이 감소하기 때문이다. 그런데, ‘주주 간의 의결권구속계약’의 구속력은 눈에 띄게 약하다. 의결권구속계약이 위반을 앞두고 있는 경우, 많지 않은 하급심 판결례들은 의결권행사가처분신청에 대해서 적대적인 입장을 취한다. 곧 강제이행을 구하려면 민법 제389조 제2항에서 정하는 의사의 진술을 명하는 판결을 받은 후 그 판결이 확정될 때까지 기다려야 하는데, 의결권 행사가 시의성과 시급성을 특징으로 하는 점에 비추어 구제수단으로서 강제이행을 인정하지 않는 것과 다름없다. 本稿에서는 Ⅱ.에서는 계약의 구속력과 효율성의 관계를 살피고, Ⅲ.에서는 계약 위반의 구제수단으로서 특정이행·금지명령과 손해배상 사이의 비교에 관한 칼라브레시·멜라메드와 율렌의 논의를 소개하였다. Ⅳ.에서는 의결권구속계약이 가치의 변동성이 큰 폐쇄회사에서 주로 체결되며, 이러한 상황 속에서 의결권구속계약에서 강제이행이 법경제학적으로 효율적인 구제수단이 된다는 주장을 거래비용의 관점에서의 분석과 게임 나무적 표현을 통하여 입증해보였다. 이로써, 주주 간의 의결권구속계약의 구속력이 너무 약하게 인정되며, 이것이 거래비용의 급격한 증가로 이어지고 있다는 결론에 도달했다. 本稿는 비단 주주간 계약의 하위 개념으로서의 의결권구속계약에서 의결권행사가처분이 인정되어야 한다는 주장을 하였을 뿐만 아니라, 법경제학적 시각에서 의결권구속계약을 연구 대상으로 삼아 계약법 전반에 대한 논의를 음미해보며, 오늘날 계약법의 일반적인 유용성과 타당성까지를 입증해보인 의의가 있다. 또 한편으로 本稿에서는 “게임 나무적 표현”이라는 새로운 법경제학적 연구방법론을 제시해본 의의가 있다.
전상용,류호선,김영민,오경주 계명대학교 자연과학연구소 2020 Quantitative Bio-Science Vol.39 No.1
We term a stock that rises more than 10 times over a short period (less than 3 years) as a ten-bagger stock. Several tenbagger stocks have existed since the past, and will continue to do so. To identify the characteristics of the ten-bagger stocks that appeared since the early 2000s to the most recent ones, and ultimately, to predict future ten-bagger stocks, we tried to find a connection with the Russell 2000 index. We used Pettitt’s test to find the change-point in the Russell 2000 industry index and found a connection with the ten-bagger stocks. This study attempts to predict ten-bagger stocks through case analysis and draws two conclusions. Through this analysis, we could identify new growth sectors and stocks in KOSPI market such as 1st somatic analyzer, 1st lactic acid bacterium in 2012, 1st anode material company, 1st cathode material company, and No. 1 stomach anticancer drugs company in 2017.
A nanomedicinal arsenal for cancer imaging and therapy
전상용 한국공업화학회 2015 한국공업화학회 연구논문 초록집 Vol.2015 No.0
There has been a surge of interest in the development of biomaterials for medical applications, including drug or gene delivery, medical implants, tissue engineering, and diagnostics. Some of them are already in the market or under development in great anticipation. In this seminar I will present some recent progress made in my lab aiming to develop nanoparticle-based nanomedicine for cancer imaging and therapy. A major focus will be given to the development of functional molecules and materials for biomedical applications including diagnostics, drug delivery, and in vivo imaging. The topics of this seminar will include: (1) Biomedical applications of a novel class of high-affinity peptides (aptides) (2) Multistimuli-responsive nanovesicles for anticancer and anti-inflammatory therapy (3) Nontoxic, small lipid nanoparticles as a systemic delivery platform for RNAi therapeutics.